Even if regulatory approvals are obtained, there is a risk that (i) the agreement with Galderma Pharma S.A. pertaining to its CTA product, will not result in meaningful sales of the company's products, (ii) the company will be unable to achieve performance and sales threshold milestones in its distribution agreements, (iii) competitive products will adversely impact the company's product sales, or